QUOTE AND NEWS
Forbes  Jun 24  Comment 
On Friday, leading North American heavy-duty transit bus manufacturer New Flyer Industries (TSX:NFI, OTC:NFYEF) announced the acquisition of its third largest competitor, North American Bus Industries from private equity firm Cerberus Capital.
Benzinga  Nov 9  Comment 
Nabi Biopharmaceuticals (NASDAQ: NABI) announced today the effectiveness of its six-to-one reverse stock split (the "Reverse Stock Split") of Nabi common stock, which became effective as of 4:59 p.m., Eastern Standard Time, on November 8, 2012...
StreetInsider.com  Nov 8  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Nabi+Biopharmaceuticals+%28NABI%29+Reports+Q3+Loss+of+%240.12/7860341.html for the full story.
StreetInsider.com  Nov 5  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Dividends/Nabi+Biopharmaceuticals+%28NABI%29+Declares+%241.108+Special+Dividend%3B+65.2%25+Yield/7843047.html for the full story.
Benzinga  Oct 23  Comment 
Nabi Biopharmaceuticals (NASDAQ: NABI) announced today the results of the reconvened special meeting of Nabi stockholders held on October 22, 2012 (the "Nabi Special Meeting"). Nabi also announced that the stockholders of Biota Holdings Limited...
StreetInsider.com  Oct 17  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Nabi+Biopharma+%28NABI%29+Says+NicVAX+Phase+II+Missed+Primary+Endpoint/7798039.html for the full story.
StreetInsider.com  Oct 16  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Dividends/Nabi+Biopharmaceuticals+%28NABI%29+Plans+Dividend+of+%240.99+to+%241.1/7797023.html for the full story.
StreetInsider.com  Sep 6  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Management+Changes/Nabi+%28NABI%29+To+Bring+in+Russell+Plumb+as+President+and+CEO+Post-Merger/7709860.html for the full story.
StreetInsider.com  Aug 23  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Nabi+Biopharma+%28NABI%29+Sends+Shareholder+Letter%3B+Urges+Voting+on+White+Proxy/7681050.html for the full story.
The Australian  Jul 26  Comment 
THE US ambitions of Biota, including a merger with Nabi Biopharmaceuticals, could be jeopardised by an investor attack.




 
TOP CONTRIBUTORS

Nabi Biopharmaceuticals develops vaccines addressing the unmet medical need of nicotine addiction. Its current sole remaining product in development is NicVAX® [Nicotine Conjugate Vaccine], an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology.[1] With over 1.3 billion smokers worldwide today and nearly five million tobacco-related deaths each year, tobacco addiction has been a hot topic for many countries around the world, prompting a need for medication provided by companies such as Nabi. As a result, the FDA has approved a Fast Track Designation for its drugs developed to fight nicotine addiction.[2]

Business Growth

Nabi has a working relationship with GlaxoSmithKline (GSK) whereby revenues recognized under its drugs, PentaStaph and NicVAX, pertain to agreements where fees are recognized as revenue ratably over the period of participation in joint steering committees.

Trends and Forces

A Wide Need for Smokers to Quit Mixed with Few Methods of Quitting Provides Opportunity for NABI

The U.S. Centers for Disease Control and Prevention (CDC) estimates that, among the 43.4 million adult smokers in the United States, roughly 70% want to quit. Unfortunately, despite this need, only 5% of those who attempt to quit remain smoke-free after 12 months, showing that current nicotine treatment methods are inadequate to match the millions of Americans desiring to quit. Most current therapies use nicotine replacement products such as patches, lozenges or chewing gum, but all have shown limited efficacy. Should NicVAX be approved, the upside potentials for mass distribution of this drug could mean unprecedented change in an industry that has not yet found a sustainable solution to quitting tobacco related products.[3]

Favorable Government Support for Nicotine Addiction Treatment is Beneficial for NABI

Tobacco use is considered the number one preventable cause of death in the United States, and it is estimated that smoking results in an annual health-related economic cost in the U.S. of approximately $193 billion.[4] As a result, the Food and Drug Administration (FDA) is more inclined to grant a Fast Track Designation for products like NicVAX, which will speed up the approval process. Further, but being able to speed up the approval process, Nabi will have more time to enjoy the patent benefits should the drug be approved.

Competition

Nabi competes with other bio-pharmaceutical companies that try to achieve working relationships with pharma giants such as GlaxoSmithKline (GSK) and Merck (MRK), as well as subsidiaries of pharma giants that currently market addition-related treatment drugs such as:




References

  1. NABI 10-K FY2010, Pg 1
  2. NABI 10-K FY2010, Pg 29
  3. NABI 10-K FY2010, Pg 30
  4. NABI 10-K FY2010, Pg 30
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki